Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders
- PMID: 38254872
- PMCID: PMC10814653
- DOI: 10.3390/cancers16020383
Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders
Abstract
Radiotherapy is the primary treatment modality for non-metastatic nasopharyngeal carcinoma (NPC) across all TN-stages. Locoregional control rates have been impressive even from the 2D radiotherapy (RT) era, except when the ability to deliver optimal dose coverage to the tumor is compromised. However, short- and long-term complications following head and neck RT are potentially debilitating, and thus, there has been much research investigating technological advances in RT delivery over the past decades, with the primary goal of limiting normal tissue damage. On this note, with a plateau in gains of therapeutic ratio by modern RT techniques, future advances have to be focused on individualization of RT, both in terms of dose prescription and the delineation of target volumes. In this review, we analyzed the guidelines and evidence related to contouring methods, and dose prescription for early and locoregionally advanced (LA-) NPC. Next, with the preference for induction chemotherapy (IC) in patients with LA-NPC, we assessed the evidence concerning radiotherapy adaptations guided by IC response, as well as functional imaging and contour changes during treatment. Finally, we discussed on RT individualization that is guided by EBV DNA assessment, and its importance in the era of combinatorial immune checkpoint blockade therapy with RT.
Keywords: nasopharyngeal carcinoma; radiotherapy; response adaptation; toxicity; treatment individualization.
Conflict of interest statement
Melvin L.K. Chua reports personal fees from Astellas, Janssen, Bayer, Pfizer, BeiGene, MSD, Varian, IQVIA, Telix Pharmaceuticals, personal fees and non-financial support from AstraZeneca, non-financial support from Decipher Biosciences, non-financial support from MedLever, consults for immunoSCAPE Inc., and is a co-inventor of the patent of a High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Sample (10202107837T), Singapore and serves on the Board of Directors of Digital Life Line Pte Ltd. that owns the licensing agreement of the patent, outside the submitted work. PL Yip, R You, and MY Chen declared no conflicts of interest.
References
-
- Amin M.B., Edge S.B., Greene F.L., Byrd D.R., Brookland R.K., Washington M.K., Gershenwald J.E., Compton C.C., Hess K.R., Sullivan D.C. AJCC Cancer Staging Manual. Springer International Publishing; Berlin/Heidelberg, Germany: 2018.
-
- Huang S.H., Jacinto J.C.K., O’Sullivan B., Su J., Kim J., Ringash J., Spreafico A., Yu E., Perez-Ordonez B., Weinreb I., et al. Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. Cancer. 2022;128:2908–2921. doi: 10.1002/cncr.34266. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
